Key Highlights

  • Biote reported second-quarter 2026 Revenue down about 9.5% to roughly $44.2 million and swung to a loss.
  • A product recall was cited as the main driver of the sales pressure during the quarter.
  • Biote delivers hormone-optimization therapy primarily through hormone pellets administered by a network of trained clinicians.
  • BTMD shares rose on August 27, 2026, as investors looked past the near-term disruption.

Biote Corp. (NASDAQ:BTMD), a company focused on hormone-optimization therapy delivered through a network of trained practitioners, hit a setback in the second quarter of 2026 as a product recall weighed on sales and pushed it to a loss. The stock rose anyway, as investors appeared to look past the near-term disruption toward the company's differentiated, wellness-oriented business.

Biote offers exposure to the hormone-optimization and healthy-aging market through a practitioner-network model, but the recent recall and revenue decline have introduced near-term uncertainty even as shares gained.

A recall weighs on results, but shares gain

For the second quarter of 2026, Biote reported revenue down about 9.5% to roughly $44.2 million and swung to a loss, with reporting attributing the pressure to a product recall that hit sales. Biote provides bioidentical hormone-replacement therapy, primarily through hormone pellets administered by a network of trained clinicians, along with dietary supplements, targeting men and women seeking to address symptoms associated with hormonal changes and aging.

The company's model involves Training and supporting practitioners who deliver its therapies, creating a Recurring Revenue stream tied to procedures and product sales. A recall can disrupt that stream and dent confidence in the near term, but the stock's gain suggests investors see the disruption as temporary.

Business and financial position

Biote operates a differentiated model in the hormone-optimization market, generating revenue from the therapies and supplements delivered through its network of trained practitioners. Its results depend on the number and productivity of practitioners, patient Demand for hormone-optimization and wellness services, product Supply and quality, and its ability to grow while managing costs.

Stock-market context

BTMD rose on August 27, 2026, even after the recall-driven revenue decline. Small- and mid-cap healthcare and wellness stocks can be volatile around Earnings and operational disruptions, and a stock can gain if investors view a setback as temporary and see continued underlying demand. The bull case rests on the differentiated model and demand for hormone-optimization and healthy-aging services; the bear case focuses on the recall disruption, revenue decline and execution.

What investors should watch

The key signals are the resolution and impact of the recall, the recovery in revenue, the growth and productivity of the practitioner network, and supplement sales. Investors will be monitoring margins, cash flow, Capital allocation, and competition in hormone-optimization and wellness.

Investors Betting the Setback Is Temporary

Product recalls are among the more damaging events for a company built on practitioner and patient trust, since they can disrupt supply, dent confidence and take time to work through. Biote's differentiated model still addresses genuine demand in the healthy-aging market, and the August 27 gain suggests the market is betting that the recall's impact will prove contained rather than lasting.